Modified HDL: Biological and physiopathological consequences

Giuseppe Danilo Norata, Angela Pirillo, Alberico Luigi Catapano

Research output: Contribution to journalArticle

Abstract

Epidemiological and clinical studies have demonstrated the inverse association between HDL cholesterol levels (HDL-C) and the risk of coronary heart disease (CHD). This correlation is believed to relate to the ability of HDL to promote reverse cholesterol transport. Remodeling of HDL due to chemical/physical modifications can dramatically affect its functions, leading to dysfunctional HDL that could promote atherogenesis. HDL modification can be achieved by different means: (i) non-enzymatic modifications, owing to the presence of free metal ions in the atherosclerotic plaques; (ii) cell-associated enzymes, which can degrade the apoproteins without significant changes in the lipid moiety, or can alternatively induce apoprotein cross-linking and lipid oxidation; (iii) association with acute phase proteins, whose circulating levels are significantly increased during inflammation which may modify HDL structure and functions; and (iv) metabolic modifications, such as glycation that occurs under hyperglycaemic conditions. Available data suggest that HDL can easily be modified losing their anti-atherogenic activities. These observation results mainly from in vitro studies, while few in vivo data, are available. Furthermore the in vivo mechanisms involved in HDL modification are ill understood. A better knowledge of these pathways may provide possible therapeutic target aimed at reducing HDL modification.

Original languageEnglish
Pages (from-to)371-386
Number of pages16
JournalNutrition, Metabolism and Cardiovascular Diseases
Volume16
Issue number5
DOIs
Publication statusPublished - Jul 2006

Fingerprint

apoproteins
Apoproteins
Lipids
atherogenesis
glycation
acute phase proteins
Acute-Phase Proteins
Atherosclerotic Plaques
metal ions
crosslinking
high density lipoprotein cholesterol
in vitro studies
epidemiological studies
HDL Cholesterol
Coronary Disease
Epidemiologic Studies
clinical trials
Atherosclerosis
lipid peroxidation
inflammation

Keywords

  • Glycation
  • Modified HDL
  • Myeloperoxidase
  • Paraoxonase

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine (miscellaneous)
  • Food Science
  • Endocrinology, Diabetes and Metabolism

Cite this

Modified HDL : Biological and physiopathological consequences. / Norata, Giuseppe Danilo; Pirillo, Angela; Catapano, Alberico Luigi.

In: Nutrition, Metabolism and Cardiovascular Diseases, Vol. 16, No. 5, 07.2006, p. 371-386.

Research output: Contribution to journalArticle

@article{f1e59bec677b4d3984429dabb7dc67fe,
title = "Modified HDL: Biological and physiopathological consequences",
abstract = "Epidemiological and clinical studies have demonstrated the inverse association between HDL cholesterol levels (HDL-C) and the risk of coronary heart disease (CHD). This correlation is believed to relate to the ability of HDL to promote reverse cholesterol transport. Remodeling of HDL due to chemical/physical modifications can dramatically affect its functions, leading to dysfunctional HDL that could promote atherogenesis. HDL modification can be achieved by different means: (i) non-enzymatic modifications, owing to the presence of free metal ions in the atherosclerotic plaques; (ii) cell-associated enzymes, which can degrade the apoproteins without significant changes in the lipid moiety, or can alternatively induce apoprotein cross-linking and lipid oxidation; (iii) association with acute phase proteins, whose circulating levels are significantly increased during inflammation which may modify HDL structure and functions; and (iv) metabolic modifications, such as glycation that occurs under hyperglycaemic conditions. Available data suggest that HDL can easily be modified losing their anti-atherogenic activities. These observation results mainly from in vitro studies, while few in vivo data, are available. Furthermore the in vivo mechanisms involved in HDL modification are ill understood. A better knowledge of these pathways may provide possible therapeutic target aimed at reducing HDL modification.",
keywords = "Glycation, Modified HDL, Myeloperoxidase, Paraoxonase",
author = "Norata, {Giuseppe Danilo} and Angela Pirillo and Catapano, {Alberico Luigi}",
year = "2006",
month = "7",
doi = "10.1016/j.numecd.2006.01.012",
language = "English",
volume = "16",
pages = "371--386",
journal = "Nutrition, Metabolism and Cardiovascular Diseases",
issn = "0939-4753",
publisher = "Elsevier B.V.",
number = "5",

}

TY - JOUR

T1 - Modified HDL

T2 - Biological and physiopathological consequences

AU - Norata, Giuseppe Danilo

AU - Pirillo, Angela

AU - Catapano, Alberico Luigi

PY - 2006/7

Y1 - 2006/7

N2 - Epidemiological and clinical studies have demonstrated the inverse association between HDL cholesterol levels (HDL-C) and the risk of coronary heart disease (CHD). This correlation is believed to relate to the ability of HDL to promote reverse cholesterol transport. Remodeling of HDL due to chemical/physical modifications can dramatically affect its functions, leading to dysfunctional HDL that could promote atherogenesis. HDL modification can be achieved by different means: (i) non-enzymatic modifications, owing to the presence of free metal ions in the atherosclerotic plaques; (ii) cell-associated enzymes, which can degrade the apoproteins without significant changes in the lipid moiety, or can alternatively induce apoprotein cross-linking and lipid oxidation; (iii) association with acute phase proteins, whose circulating levels are significantly increased during inflammation which may modify HDL structure and functions; and (iv) metabolic modifications, such as glycation that occurs under hyperglycaemic conditions. Available data suggest that HDL can easily be modified losing their anti-atherogenic activities. These observation results mainly from in vitro studies, while few in vivo data, are available. Furthermore the in vivo mechanisms involved in HDL modification are ill understood. A better knowledge of these pathways may provide possible therapeutic target aimed at reducing HDL modification.

AB - Epidemiological and clinical studies have demonstrated the inverse association between HDL cholesterol levels (HDL-C) and the risk of coronary heart disease (CHD). This correlation is believed to relate to the ability of HDL to promote reverse cholesterol transport. Remodeling of HDL due to chemical/physical modifications can dramatically affect its functions, leading to dysfunctional HDL that could promote atherogenesis. HDL modification can be achieved by different means: (i) non-enzymatic modifications, owing to the presence of free metal ions in the atherosclerotic plaques; (ii) cell-associated enzymes, which can degrade the apoproteins without significant changes in the lipid moiety, or can alternatively induce apoprotein cross-linking and lipid oxidation; (iii) association with acute phase proteins, whose circulating levels are significantly increased during inflammation which may modify HDL structure and functions; and (iv) metabolic modifications, such as glycation that occurs under hyperglycaemic conditions. Available data suggest that HDL can easily be modified losing their anti-atherogenic activities. These observation results mainly from in vitro studies, while few in vivo data, are available. Furthermore the in vivo mechanisms involved in HDL modification are ill understood. A better knowledge of these pathways may provide possible therapeutic target aimed at reducing HDL modification.

KW - Glycation

KW - Modified HDL

KW - Myeloperoxidase

KW - Paraoxonase

UR - http://www.scopus.com/inward/record.url?scp=33745610718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745610718&partnerID=8YFLogxK

U2 - 10.1016/j.numecd.2006.01.012

DO - 10.1016/j.numecd.2006.01.012

M3 - Article

C2 - 16829346

AN - SCOPUS:33745610718

VL - 16

SP - 371

EP - 386

JO - Nutrition, Metabolism and Cardiovascular Diseases

JF - Nutrition, Metabolism and Cardiovascular Diseases

SN - 0939-4753

IS - 5

ER -